Meta-Analysis

Pneumonitis with combined immune checkpoint inhibitors and chemoradiotherapy in locally advanced non-small-cell lung cancer: a systematic review and meta-analysis

Department of Radiation Oncology, Shandong Cancer Hospital & Institute, Shandong First Medical University & Shandong Academy of Medical Science, Jinan, 250117, China

‡Authors contributed equally

Search for more papers by this author

Butuo Li‡

Department of Radiation Oncology, Shandong Cancer Hospital & Institute, Shandong First Medical University & Shandong Academy of Medical Science, Jinan, 250117, China

‡Authors contributed equally

Search for more papers by this author

Yiyue Xu

Department of Radiation Oncology, Shandong Cancer Hospital & Institute, Shandong First Medical University & Shandong Academy of Medical Science, Jinan, 250117, China

Search for more papers by this author

Bing Zou

Department of Radiation Oncology, Shandong Cancer Hospital & Institute, Shandong First Medical University & Shandong Academy of Medical Science, Jinan, 250117, China

Search for more papers by this author

Bingjie Fan

Department of Radiation Oncology, Shandong Cancer Hospital & Institute, Shandong First Medical University & Shandong Academy of Medical Science, Jinan, 250117, China

Search for more papers by this author

Chunni Wang

Department of Radiation Oncology, Shandong Cancer Hospital & Institute, Shandong First Medical University & Shandong Academy of Medical Science, Jinan, 250117, China

Search for more papers by this author

Linlin Wang

*Author for correspondence: Tel.: +86 137 9318 7739;

E-mail Address: wanglinlinatjn@163.com

https://orcid.org/0000-0002-2231-6642

Department of Radiation Oncology, Shandong Cancer Hospital & Institute, Shandong First Medical University & Shandong Academy of Medical Science, Jinan, 250117, China

Search for more papers by this author

Published Online:9 Jun 2023https://doi.org/10.2217/fon-2022-1274

View article

Abstract

Aims: This study systematically evaluated cases of pneumonitis following combined immune checkpoint inhibitors (ICI) and chemoradiotherapy (CRT) for locally advanced non-small-cell lung cancer (LA-NSCLC). Methods: Studies from Embase, PubMed and the Cochrane Library on patients with LA-NSCLC who received CRT and ICIs were reviewed. The primary outcomes were rates of all-grade, grade 3–5 and grade 5 pneumonitis. Results: Overall, 35 studies involving 5000 patients were enrolled. The pooled rates of all-grade, grade 3–5 and grade 5 pneumonitis were 33.0% (95% CI: 23.5–42.6), 6.1% (95% CI: 4.7–7.4) and 0.8% (95% CI: 0.3–1.2), respectively, with 7.6% of patients discontinuing ICIs because of pneumonitis. Conclusion: The incidence rates of pneumonitis following combined CRT and ICIs for LA-NSCLC were acceptable. However, the pulmonary toxicity of concurrent CRT and nivolumab plus ipilimumab should be noted.

Plain language summary

Combined immune checkpoint inhibitors (ICI) and chemoradiotherapy (CRT) may cause severe pneumonitis due to overlapped pulmonary toxicity. However, the safety data on pneumonitis are limited to a small number of prospective clinical trials and retrospective studies with limited evidence. Thus we conducted a systematic review of pneumonitis in relation to the combination treatment. A total of 35 studies, involving 5000 patients, were included for the final analysis. The pooled rates of all-grade, grade 3–5 and grade 5 pneumonitis were 33.0, 6.1 and 0.8%, respectively, and 7.6% of patients stopped taking ICIs because of pneumonitis. The pneumonitis rates following combined CRT and ICIs for LA-NSCLC were acceptable, but the pulmonary toxicity of concurrent CRT and nivolumab plus ipilimumab should be noted.

Keywords:

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

1. Bobbili P, Ryan K, Duh MS et al. Treatment patterns and overall survival among patients with unresectable, stage III non-small-cell lung cancer. Future Oncol. 15(29), 3381–3393 (2019).
CASGoogle Scholar
2. Chansky K, Detterbeck FC, Nicholson AG et al. The IASLC Lung Cancer Staging Project: external validation of the revision of the TNM stage groupings in the Eighth Edition of the TNM Classification of Lung Cancer. J. Thorac. Oncol. 12(7), 1109–1121 (2017).
MedlineGoogle Scholar
3. Curran WJ Jr, Paulus R, Langer CJ et al. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J. Natl Cancer Inst. 103(19), 1452–1460 (2011).
Medline CASGoogle Scholar
4. Bradley JD, Paulus R, Komaki R et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol. 16(2), 187–199 (2015).
Medline CASGoogle Scholar
5. Spigel DR, Faivre-Finn C, Gray JE et al. Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. J. Clin. Oncol. 40(12), 1301–1311 (2022). • The PACIFIC study led to a new standard of consolidation immunotherapy 1 year after concurrent chemoradiotherapy for locally advanced non-small-cell lung cancer.
Medline CASGoogle Scholar
6. Ko EC, Raben D, Formenti SC. The integration of radiotherapy with immunotherapy for the treatment of non-small cell lung cancer. Clin. Cancer Res. 24(23), 5792–5806 (2018).
Medline CASGoogle Scholar
7. Theelen W, Chen D, Verma V et al. Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Respir. Med. 9(5), 467–475 (2021).
Medline CASGoogle Scholar
8. Barker HE, Paget JT, Khan AA, Harrington KJ. The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. Nat. Rev. Cancer 15(7), 409–425 (2015).
Medline CASGoogle Scholar
9. Santivasi WL, Xia F. Ionizing radiation-induced DNA damage, response, and repair. Antioxid. Redox Signal. 21(2), 251–259 (2014).
Medline CASGoogle Scholar
10. Rodríguez-Ruiz ME, Vanpouille-Box C, Melero I, Formenti SC, Demaria S. Immunological mechanisms responsible for radiation-induced abscopal effect. Trends Immunol. 39(8), 644–655 (2018).
Medline CASGoogle Scholar
11. Kaur P, Asea A. Radiation-induced effects and the immune system in cancer. Front. Oncol. 2, 191 (2012).
Medline CASGoogle Scholar
12. Daly ME, Monjazeb AM, Kelly K. Clinical trials integrating immunotherapy and radiation for non-small-cell lung cancer. J. Thorac. Oncol. 10(12), 1685–1693 (2015).
Medline CASGoogle Scholar
13. Shaverdian N, Lisberg AE, Bornazyan K et al. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol. 18(7), 895–903 (2017).
Medline CASGoogle Scholar
14. Shaverdian N, Beattie J, Thor M et al. Safety of thoracic radiotherapy in patients with prior immune-related adverse events from immune checkpoint inhibitors. Ann. Oncol. 31(12), 1719–1724 (2020).
Medline CASGoogle Scholar
15. Hanania AN, Mainwaring W, Ghebre YT, Hanania NA, Ludwig M. Radiation-induced lung injury: assessment and management. Chest 156(1), 150–162 (2019).
MedlineGoogle Scholar
16. Weber JS, Yang JC, Atkins MB, Disis ML. Toxicities of immunotherapy for the practitioner. J. Clin. Oncol. 33(18), 2092–2099 (2015).
Medline CASGoogle Scholar
17. Li M, Gan L, Song A, Xue J, Lu Y. Rethinking pulmonary toxicity in advanced non-small cell lung cancer in the era of combining anti-PD-1/PD-L1 therapy with thoracic radiotherapy. Biochim. Biophys. Acta Rev. Cancer 1871(2), 323–330 (2019). •• Demonstrated that for patients with locally advanced non-small-cell lung cancer treated with combined chemoradiotherapy and immune checkpoint inhibitors, treatment-related adverse pulmonary events should be of particular concern because both treatments may simultaneously induce pulmonary toxicity.
Medline CASGoogle Scholar
18. Page MJ, Moher D, Bossuyt PM et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ 372, n160 (2021). •• Provides the research methods for this study.
MedlineGoogle Scholar
19. Page MJ, McKenzie JE, Bossuyt PM et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372, n71 (2021). •• Provides the research methods for this study.
MedlineGoogle Scholar
20. Yan M, Durm GA, Mamdani H et al. Consolidation nivolumab/ipilimumab versus nivolumab following concurrent chemoradiation in patients with unresectable stage III NSCLC: a planned interim safety analysis from the BTCRC LUN 16-081 trial. J. Clin. Oncol. 38(15), 9010–9010 (2020).
Google Scholar
21. Herbst RS, Majem M, Barlesi F et al. COAST: an open-label, phase II, multidrug platform study of durvalumab alone or in combination with oleclumab or monalizumab in patients with unresectable, stage III non-small-cell lung cancer. J. Clin. Oncol. 40(29), 3383–3393 (2022).
Medline CASGoogle Scholar
22. Liveringhouse C, Lam NB, Rosenberg SA et al. Prospective phase I/II study of radiation and chemotherapy with ipilimumab followed by nivolumab for patients with stage III unresectable NSCLC. Int. J. Radiat. Oncol. Biol. Phys. 111(3), S3–S4 (2021).
Google Scholar
23. Garassino MC, Mazieres J, Reck M et al. Durvalumab after sequential chemoradiotherapy in stage III, unresectable NSCLC: the phase 2 PACIFIC-6 trial. J. Thorac. Oncol. 17(12), 1415–1427 (2022).
Medline CASGoogle Scholar
24. Christoph DC, Girard N, Smit HJM et al. Pacific-R real-world study: treatment duration and interim analysis of progression-free survival in unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy. Oncol. Res. Treat. 44(Suppl. 2), 53 (2021).
Google Scholar
25. Bruni A, Scotti V, Borghetti P et al. A real-world, multicenter, observational retrospective study of durvalumab after concomitant or sequential chemoradiation for unresectable stage III non-small cell lung cancer. Front. Oncol. 11, 744956 (2021).
Medline CASGoogle Scholar
26. Wass R, Hochmair M, Kaiser B et al. Durvalumab after sequential high dose chemoradiotherapy versus standard of care (SoC) for stage III NSCLC: a bi-centric trospective comparison focusing on pulmonary toxicity. Cancers (Basel) 14(13), 3226 (2022).
Medline CASGoogle Scholar
27. Zhou Q, Chen M, Jiang O et al. Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 23(2), 209–219 (2022).
Medline CASGoogle Scholar
28. Hwang WL, Pike LRG, Royce TJ, Mahal BA, Loeffler JS. Safety of combining radiotherapy with immune-checkpoint inhibition. Nat. Rev. Clin. Oncol. 15(8), 477–494 (2018).
MedlineGoogle Scholar
29. Deng L, Liang H, Burnette B et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J. Clin. Invest. 124(2), 687–695 (2014).
Medline CASGoogle Scholar
30. Sanmamed MF, Chen L. A paradigm shift in cancer immunotherapy: from enhancement to normalization. Cell 175(2), 313–326 (2018).
Medline CASGoogle Scholar
31. Kuang Y, Pierce CM, Chang HC et al. Chemoradiation-induced pneumonitis in patients with unresectable stage III non-small cell lung cancer: a systematic literature review and meta-analysis. Lung Cancer 174, 174–185 (2022).
Medline CASGoogle Scholar
32. Park K, Vansteenkiste J, Lee KH et al. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS. Ann. Oncol. 31(2), 191–201 (2020).
Medline CASGoogle Scholar
33. Daly ME, Singh N, Ismaila N et al. Management of stage III non-small-cell lung cancer: ASCO Guideline. J. Clin. Oncol. 40(12), 1356–1384 (2022).
MedlineGoogle Scholar
34. Walraven I, Damhuis RA, Ten Berge MG et al. Treatment variation of sequential versus concurrent chemoradiotherapy in stage III non-small cell lung cancer patients in The Netherlands and Belgium. Clin. Oncol. 29(11), e177–e185 (2017).
CASGoogle Scholar
35. Hung A, Lee KM, Lynch JA et al. Chemoradiation treatment patterns among United States Veteran Health Administration patients with unresectable stage III non-small cell lung cancer. BMC Cancer 21(1), 824 (2021).
MedlineGoogle Scholar
36. Spencer A, Williams J, Samuel R, Boon IS, Clarke K, Jain P. Concurrent versus sequential chemoradiotherapy for unresectable locally advanced stage III non-small cell lung cancer: retrospective analysis in a single United Kingdom cancer centre. Cancer Treat. Res. Commun. 29, 100460 (2021).
MedlineGoogle Scholar
37. Conibear J. Rationale for concurrent chemoradiotherapy for patients with stage III non-small-cell lung cancer. Br. J. Cancer 123(Suppl. 1), 10–17 (2020).
MedlineGoogle Scholar
38. Weinmann SC, Pisetsky DS. Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors. Rheumatology 58(Suppl. 7), vii59–vii67 (2019).
Medline CASGoogle Scholar
39. Durm GA, Mamdani H, Althouse SK et al. Consolidation nivolumab plus ipilimumab or nivolumab alone following concurrent chemoradiation for patients with unresectable stage III non-small cell lung cancer: BTCRC LUN 16-081. Journal of Clinical Oncology. 40(Suppl. 16), 8509 (2022).
Google Scholar
40. Xiao Y, Yu S, Zhu B et al. RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance. J. Exp. Med. 211(5), 943–959 (2014).
Medline CASGoogle Scholar
41. Muraro E, Romanò R, Fanetti G et al. Tissue and circulating PD-L2: moving from health and immune-mediated diseases to head and neck oncology. Crit. Rev. Oncol. Hematol. 175, 103707 (2022).
MedlineGoogle Scholar
42. Mayoux M, Roller A, Pulko V et al. Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy. Sci. Transl. Med. 12(534), eaav7431 (2020).
Medline CASGoogle Scholar
43. Takeuchi M, Doi T, Obayashi K et al. Soluble PD-L1 with PD-1-binding capacity exists in the plasma of patients with non-small cell lung cancer. Immunol. Lett. 196, 155–160 (2018).
Medline CASGoogle Scholar
44. Jalali S, Price-Troska T, Paludo J et al. Soluble PD-1 ligands regulate T-cell function in Waldenstrom macroglobulinemia. Blood Adv. 2(15), 1985–1997 (2018).
Medline CASGoogle Scholar
45. Senan S, Brade A, Wang LH et al. PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer. Journal of clinical oncology 34(9), 953–62 (2016).
Medline CASGoogle Scholar
46. Eichkorn T, Bozorgmehr F, Regnery S et al. Consolidation Immunotherapy After Platinum-Based Chemoradiotherapy in Patients With Unresectable Stage III Non-Small Cell Lung Cancer-Cross-Sectional Study of Eligibility and Administration Rates. Frontiers in oncology 10, 586449 (2020).
MedlineGoogle Scholar
47. Jabbour SK, Lee KH, Frost N et al. Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer: The Phase 2 KEYNOTE-799 Nonrandomized Trial. JAMA Oncol. 7(9), 1–9 (2021).
MedlineGoogle Scholar
48. Ryckman JM, Baine M, Carmicheal J et al. Correlation of dosimetric factors with the development of symptomatic radiation pneumonitis in stereotactic body radiotherapy. Radiation oncology. 15(1), 33 ( 2020).
Medline CASGoogle Scholar
49. Pan WY, Bian C, Zou GL et al. Combing NLR, V20 and mean lung dose to predict radiation induced lung injury in patients with lung cancer treated with intensity modulated radiation therapy and chemotherapy. Oncotarget. 8(46), 81387–93 (2017).
MedlineGoogle Scholar
50. Chun SG, Hu C, Choy H et al. Impact of intensity-modulated radiation therapy technique for locally advanced non-small-cell lung cancer: a secondary analysis of the NRG Oncology RTOG 0617 randomized clinical trial. J. Clin. Oncol. 35(1), 56–62 (2017).
MedlineGoogle Scholar
51. Wurstbauer K, Kazil M, Meinschad M et al. Locally advanced NSCLC: a plea for sparing the ipsilateral normal lung-prospective, clinical trial with DART-bid (dose-differentiated accelerated radiation therapy, 1.8 Gy twice daily) by VMAT. Radiat. Oncol. 17(1), 120 (2022).
Medline CASGoogle Scholar
52. Baumann BC, Mitra N, Harton JG et al. Comparative effectiveness of proton vs photon therapy as part of concurrent chemoradiotherapy for locally advanced cancer. JAMA Oncol. 6(2), 237–246 (2020).
MedlineGoogle Scholar
53. Bradley J, Bae K, Choi N et al. A phase II comparative study of gross tumor volume definition with or without PET/CT fusion in dosimetric planning for non-small-cell lung cancer (NSCLC): primary analysis of Radiation Therapy Oncology Group (RTOG) 0515. International journal of radiation oncology, biology, physics 82(1), 435–41.e1 (2012).
MedlineGoogle Scholar
54. Zou L, Chu L, Xia F et al. Is clinical target volume necessary? – a failure pattern analysis in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy using intensity-modulated radiotherapy technique. Transl. Lung Cancer Res. 9(5), 1986–1995 (2020).
Medline CASGoogle Scholar
55. Xia F, Zhou L, Yang X et al. Is a clinical target volume (CTV) necessary for locally advanced non-small cell lung cancer treated with intensity-modulated radiotherapy? – a dosimetric evaluation of three different treatment plans. J. Thorac. Dis. 9(12), 5194–5202 (2017).
MedlineGoogle Scholar
56. Xue J, Du S, Lu Y, Dicker A, Lu B. Abstract 3671: anti-PD-1 treatment may potentiate the radiation-induced lung injury. Cancer Res. 77(Suppl. 13), 3671 (2017).
Google Scholar
57. van der Woude LL, Gorris MAJ, Wortel IMN et al. Tumor microenvironment shows an immunological abscopal effect in patients with NSCLC treated with pembrolizumab-radiotherapy combination. J. Immunother. Cancer 10(10), e005248 (2022). • Provides the direction for further research in the future.
MedlineGoogle Scholar
58. Xue J, Li X, Lu Y et al. Gene-modified mesenchymal stem cells protect against radiation-induced lung injury. Mol. Ther. 21(2), 456–465 (2013).
Medline CASGoogle Scholar
59. Kim KH, Pyo H, Lee H et al. Association of T cell senescence with radiation pneumonitis in patients with non-small cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 115(2), 464–475 (2022).
MedlineGoogle Scholar
60. Kim KH, Pyo H, Lee H et al. Dynamics of circulating immune cells during chemoradiotherapy in patients with non-small cell lung cancer support earlier administration of anti-PD-1/PD-L1 therapy. Int. J. Radiat. Oncol. Biol. Phys. 113(2), 415–425 (2022).
MedlineGoogle Scholar
61. Sierra-Rodero B, Cruz-Bermúdez A, Nadal E et al. Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial. J. Immunother. Cancer 9(8), e002804 (2021).
MedlineGoogle Scholar
62. Hawkins PG, Boonstra PS, Hobson ST et al. Radiation-induced lung toxicity in non-small-cell lung cancer: understanding the interactions of clinical factors and cytokines with the dose-toxicity relationship. Radiother. Oncol. 125(1), 66–72 (2017).
Medline CASGoogle Scholar
63. Kainthola A, Haritwal T, Tiwari M et al. Immunological aspect of radiation-induced pneumonitis, current treatment strategies, and future prospects. Front. Immunol. 8, 506 (2017).
MedlineGoogle Scholar
64. Brahmer JR, Lacchetti C, Schneider BJ et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. Journal of clinical oncology 36(17), 1714–68 (2018).
Medline CASGoogle Scholar

Vol. 19, No. 16

Supplemental Materials

Metrics

Downloaded 185 times

History

Received 19 December 2022

Accepted 11 April 2023

Published online 9 June 2023

Published in print May 2023

Information

Keywords

Supplementary data

To view the supplementary data that accompany this paper please visit the journal website at: www.futuremedicine.com/doi/suppl/10.2217/fon-2022-1274

Author contributions

All authors contributed to the design of this study and to the drafting of the paper and have seen and approved the final version.

Financial & competing interests disclosure

This research was supported by National Natural Science Foundation of China (grant No. 82172865), Start-up fund of Shandong Cancer Hospital (grant No. 2020-B14), Clinical Research Special Fund of Wu Jieping Medical Foundation (grant Nos. 320.6750.2021-02-51 and 320.6750.2021-17-13). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

PDF download